Regulation of the Cardiovascular Disease-Associated Protease Inhibitor Cystatin C for Therapeutic Application

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1006428

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Proteases can contribute to atherosclerosis, so they are normally controlled by the endogenous inhibitor, Cystatin C (Cst C). Some conditions cause reduction in Cst C levels and hence disease. On the other hand, excess Cst C can form toxic aggregates. In this project, we will identify mechanisms controlling Cst C expression and aggregation to find therapeutic strategies to treat cardiovascular diseases associated with Cst C.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $498,505.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Enzymes

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

aortic aneurysm | atherosclerosis | control of gene expression | dementia | immunoregulation | inflammation | inflammatory diseases | oxidative stress | protease inhibitors | protein aggregation

Related Links